Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest

Mar 30 2020

• By Brenda Sandburg

scientist in biohazard protection clothing analyzing covid 19 sample with microscope and holding coronavirus covid 19 blood sample tube on hand in laboratory, coronavirus covid 19 vaccine research — FTC and DOJ to accelerate review of COVID-19 collaborations for antitrust issues

Related Content

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

Mar 30 2020

Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug

Mar 27 2020

Related Companies

Novartis AG

Boehringer Ingelheim GmbH

bioMerieux SA

Eisai Co., Ltd.

Eli Lilly and Company

Gilead Sciences, Inc.

GSK plc

Johnson & Johnson

Merck & Co., Inc.

Merck KGaA

Pfizer Inc.

Sanofi

Additional Topics

United States Coronavirus COVID-19 Enforcement Legal Issues Policy BioPharmaceutical

More from Compliance

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.